高级检索
刘宗亮, 张仁梅, 孟庆国. 以热休克蛋白HSP70为靶点的药物研究进展[J]. 中国药科大学学报, 2017, 48(4): 416-424. DOI: 10.11665/j.issn.1000-5048.20170405
引用本文: 刘宗亮, 张仁梅, 孟庆国. 以热休克蛋白HSP70为靶点的药物研究进展[J]. 中国药科大学学报, 2017, 48(4): 416-424. DOI: 10.11665/j.issn.1000-5048.20170405
LIU Zongliang, ZHANG Renmei, MENG Qingguo. Advances of targeting heat shock protein 70 drugs[J]. Journal of China Pharmaceutical University, 2017, 48(4): 416-424. DOI: 10.11665/j.issn.1000-5048.20170405
Citation: LIU Zongliang, ZHANG Renmei, MENG Qingguo. Advances of targeting heat shock protein 70 drugs[J]. Journal of China Pharmaceutical University, 2017, 48(4): 416-424. DOI: 10.11665/j.issn.1000-5048.20170405

以热休克蛋白HSP70为靶点的药物研究进展

Advances of targeting heat shock protein 70 drugs

  • 摘要: 热休克蛋白HSP70是最保守的蛋白之一,由于在应激反应中的敏感性以及功能的多样性,HSP70逐渐成为研究的热点。HSP70蛋白可以结合错误折叠或非正常聚集的蛋白,使之正常折叠或降解,因此合理干预HSP70的生物功能,可有望治疗一系列与蛋白错误折叠相关的疾病,如肿瘤和神经退行性疾病等。目前已有多类以HSP70为靶点的药物处于临床前研究中。本文综述了HSP70的分类、结构、功能及以HSP70为靶点的药物研究进展。

     

    Abstract: Heat shock protein 70(HSP70)family is one ofthe most conserved proteinin evolutionand plays critical, role in proteostasis. HSP70 is becoming an interesting target for multiple diseases such as cancer and Alzheimer′s disease. There are many drugs targeted to HSP70 in preclinical study. In this review, the classification, the structure, the function of HSP70, and the drugs of the HSP70 family are reviewed.

     

/

返回文章
返回